The CRAFITY score emerges as a paramount prognostic indicator in hepatocellular carcinoma patients received Lenvatinib and Pembrolizumab

BackgroundLevels of C-reactive protein (CRP) and alpha-fetoprotein (AFP) in immunotherapy (CRAFITY) scores are associated with the prognosis of patients with hepatocellular carcinoma (HCC). This study aimed to explore the efficacy of lenvatinib and pembrolizumab (Len-P) based on the CRAFITY score.Me...

Полное описание

Библиографические подробности

Главные авторы:	Weijie Wu, Zhenyun Yang, Hao Zou, Teng Long, Zhongguo Zhou, Yaojun Zhang, Minshan Chen, Dandan Hu
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Frontiers Media S.A. 2024-11-01
Серии:	Frontiers in Immunology
Предметы:	hepatocellular carcinoma lenvatinib pembrolizumab C-reactive protein and A-fetoprotein in immunotherapy score overall survival
Online-ссылка:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1474456/full
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!